Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RXRX - Recursion Pharmaceuticals Inc - Ordinary Shares - Class A


IEX Last Trade
7.27
-0.140   -1.926%

Share volume: 3,550,212
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$7.41
-0.14
-1.89%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 8%
Liquidity 71%
Performance 1%
Company vs Stock growth
vs
Performance
5 Days
-6.79%
1 Month
-8.43%
3 Months
-17.93%
6 Months
-43.74%
1 Year
-17.27%
2 Year
-27.13%
Key data
Stock price
$7.27
P/E Ratio 
-5.32
DAY RANGE
N/A - N/A
EPS 
-$1.64
52 WEEK RANGE
$4.97 - $15.74
52 WEEK CHANGE
-$0.20
MARKET CAP 
1.994 B
YIELD 
N/A
SHARES OUTSTANDING 
273.940 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,241,731
AVERAGE 30 VOLUME 
$5,296,942
Company detail
CEO:
Region: US
Website: recursionpharma.com
Employees: 515
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.

Recent news